156 related articles for article (PubMed ID: 24092807)
1. BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia.
Pierceall WE; Kornblau SM; Carlson NE; Huang X; Blake N; Lena R; Elashoff M; Konopleva M; Cardone MH; Andreeff M
Mol Cancer Ther; 2013 Dec; 12(12):2940-9. PubMed ID: 24092807
[TBL] [Abstract][Full Text] [Related]
2. A novel Bim-BH3-derived Bcl-XL inhibitor: biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity.
Ponassi R; Biasotti B; Tomati V; Bruno S; Poggi A; Malacarne D; Cimoli G; Salis A; Pozzi S; Miglino M; Damonte G; Cozzini P; Spyrakis F; Campanini B; Bagnasco L; Castagnino N; Tortolina L; Mumot A; Frassoni F; Daga A; Cilli M; Piccardi F; Monfardini I; Perugini M; Zoppoli G; D'Arrigo C; Pesenti R; Parodi S
Cell Cycle; 2008 Oct; 7(20):3211-24. PubMed ID: 18843207
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs.
Ishizawa J; Kojima K; McQueen T; Ruvolo V; Chachad D; Nogueras-Gonzalez GM; Huang X; Pierceall WE; Dettman EJ; Cardone MH; Shacham S; Konopleva M; Andreeff M
PLoS One; 2015; 10(9):e0138377. PubMed ID: 26375587
[TBL] [Abstract][Full Text] [Related]
4. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
[TBL] [Abstract][Full Text] [Related]
5. Early changes in rpS6 phosphorylation and BH3 profiling predict response to chemotherapy in AML cells.
Grundy M; Jones T; Elmi L; Hall M; Graham A; Russell N; Pallis M
PLoS One; 2018; 13(5):e0196805. PubMed ID: 29723246
[TBL] [Abstract][Full Text] [Related]
6. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
[TBL] [Abstract][Full Text] [Related]
7. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.
Martínez-Cuadrón D; Gil C; Serrano J; Rodríguez G; Pérez-Oteyza J; García-Boyero R; Jiménez-Bravo S; Vives S; Vidriales MB; Lavilla E; Pérez-Simón JA; Tormo M; Colorado M; Bergua J; López JA; Herrera P; Hernández-Campo P; Gorrochategui J; Primo D; Rojas JL; Villoria J; Moscardó F; Troconiz I; Linares Gómez M; Martínez-López J; Ballesteros J; Sanz M; Montesinos P;
Leuk Res; 2019 Jan; 76():1-10. PubMed ID: 30468991
[TBL] [Abstract][Full Text] [Related]
8. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
Kornblau SM; Vu HT; Ruvolo P; Estrov Z; O'Brien S; Cortes J; Kantarjian H; Andreeff M; May WS
Clin Cancer Res; 2000 Apr; 6(4):1401-9. PubMed ID: 10778970
[TBL] [Abstract][Full Text] [Related]
9. Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia.
Pierceall WE; Lena RJ; Medeiros BC; Blake N; Doykan C; Elashoff M; Cardone MH; Walter RB
Leuk Res; 2014 May; 38(5):564-8. PubMed ID: 24636337
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction.
Pardee TS
PLoS One; 2012; 7(8):e43185. PubMed ID: 22905229
[TBL] [Abstract][Full Text] [Related]
11. Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.
Prebet T; Etienne A; Devillier R; Romeo E; Charbonnier A; D'incan E; Esterni B; Arnoulet C; Blaise D; Vey N
Cancer; 2011 Mar; 117(5):974-81. PubMed ID: 20957721
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.
Lacayo NJ; Alonzo TA; Gayko U; Rosen DB; Westfall M; Purvis N; Putta S; Louie B; Hackett J; Cohen AC; Cesano A; Gerbing R; Ravindranath Y; Dahl GV; Gamis A; Meshinchi S
Br J Haematol; 2013 Jul; 162(2):250-62. PubMed ID: 23682827
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
Dai Y; Chen S; Wang L; Pei XY; Kramer LB; Dent P; Grant S
Br J Haematol; 2011 Apr; 153(2):222-35. PubMed ID: 21375523
[TBL] [Abstract][Full Text] [Related]
14. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
15. Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy.
Kornblau SM; Minden MD; Rosen DB; Putta S; Cohen A; Covey T; Spellmeyer DC; Fantl WJ; Gayko U; Cesano A
Clin Cancer Res; 2010 Jul; 16(14):3721-33. PubMed ID: 20525753
[TBL] [Abstract][Full Text] [Related]
16. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
Kazi A; Sun J; Doi K; Sung SS; Takahashi Y; Yin H; Rodriguez JM; Becerril J; Berndt N; Hamilton AD; Wang HG; Sebti SM
J Biol Chem; 2011 Mar; 286(11):9382-92. PubMed ID: 21148306
[TBL] [Abstract][Full Text] [Related]
17. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.
Wang S; Yuan X; Liu Y; Zhu K; Chen P; Yan H; Zhang D; Li X; Zeng H; Zhao X; Chen X; Zhou G; Cao S
J Transl Med; 2019 Mar; 17(1):101. PubMed ID: 30922329
[TBL] [Abstract][Full Text] [Related]
19. Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia.
Pugliese N; Salvatore P; Iula DV; Catania MR; Chiurazzi F; Della Pepa R; Cerchione C; Raimondo M; Giordano C; Simeone L; Caruso S; Pane F; Picardi M
Cancer Med; 2017 Jul; 6(7):1500-1511. PubMed ID: 28556623
[TBL] [Abstract][Full Text] [Related]
20. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
Ewald L; Dittmann J; Vogler M; Fulda S
Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]